Published on March 10, 2010 at 8:35 AM
Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $5
million development milestone payment from Takeda Pharmaceutical Company
as part of the companies’ exclusive global agreement to develop and
commercialize Hematide™, Affymax’s investigational drug for the
treatment of anemia in chronic renal failure patients. The milestone was
achieved with the initiation of Phase 3 clinical testing of Hematide to
treat anemia in chronic renal failure patients in Japan.
Affymax and Takeda are collaborating on the development of Hematide and
will co-commercialize the product in the United States. Takeda holds an
exclusive license to develop and commercialize Hematide outside the
United States, including Japan.
In January, Affymax announced the completion of treatment and follow-up
of patients enrolled in the four-trial, Phase 3 clinical program for
Hematide in the U.S. The company expects to report topline results from
these trials in the second quarter of 2010. The U.S. Phase 3 clinical
program enrolled approximately 2,600 chronic renal failure patients at
approximately 400 clinical trial sites.
Source Affymax, Inc.